

# WADA Technical Document – TD2026INDEX

Document number:	TD2026INDEX	Version number:	3.0
Written by:	WADA Science	Approved by:	WADA Executive Committee
Reviewed by:		Effective date:	08 April 2026
Date:	08 April 2026		

## I. WADA Technical Documents

Title	Document Number	Version Number	Effective Date*
<u>Athlete Passport Management Unit</u> Requirements and Procedures	<a href="#">TD2023APMU</a>	1.0	1 January 2023
Analytical Requirements for the Hematological Module of the <i>Athlete Biological Passport</i>	<a href="#">TD2021BAR</a>	2.0	1 June 2021
Analysis, Reporting & Management of Urinary Human Chorionic Gonadotrophin (hCG) and Luteinizing Hormone (LH) Findings in <i>Male Athletes</i>	<a href="#">TD2021CG/LH</a>	1.0	1 April 2021
Dried Blood Spots (DBS) for Doping Control Requirements and Procedures for <i>Analytical Testing</i> and <i>Sample Storage</i>	<a href="#">TD2026DBS</a>	1.0	1 January 2026
<i>Decision Limits</i> for the Confirmatory Quantification of Exogenous <u>Threshold Substances</u> by Chromatography-based <u>Analytical Methods</u>	<a href="#">TD2022DL</a>	1.0	1 January 2022
Detection of Synthetic Forms of <i>Prohibited Substances</i> by GC/C/IRMS	<a href="#">TD2022IRMS</a>	1.0	1 January 2022
Measurement and Reporting of Endogenous Anabolic Androgenic Steroid (EAAS) <i>Markers</i> of the Urinary Steroid Profile	<a href="#">TD2021EAAS</a>	2.0	1 June 2021
Harmonization of Analysis and Reporting of 19-Norsteroids Related to Nandrolone	<a href="#">TD2021NA</a>	2.0	1 June 2021
Harmonization of Analysis and Reporting of Erythropoietin (EPO) and other EPO-Receptor Agonists (ERAs) by Polyacrylamide Gel Electrophoretic (PAGE) <u>Analytical Methods</u>	<a href="#">TD2024EPO</a>	1.0	15 June 2024
Human Growth Hormone (hGH) Isoform Differential Immunoassays for <i>Doping Control</i> Analyses	<a href="#">TD2021GH</a>	1.0	1 April 2021
Minimum Criteria for Chromatographic-Mass Spectrometric Confirmation of the Identity of <u>Analytes</u> for <i>Doping Control</i> Purposes	<a href="#">TD2023IDCR</a>	1.1	14 February 2023
<u>Laboratory Documentation Package</u>	<a href="#">TD2023LDOC</a>	1.1	1 October 2023
<u>Laboratory Internal Chain of Custody</u>	<a href="#">TD2021LCOC</a>	1.0	1 April 2021

# WADA Technical Document – TD2026INDEX

Document number:	TD2026INDEX	Version number:	3.0
Written by:	WADA Science	Approved by:	WADA Executive Committee
Reviewed by:		Effective date:	08 April 2026
Date:	08 April 2026		

<u>Minimum Required Performance Levels and Applicable <i>Minimum Reporting Levels</i> for <i>Non-Threshold Substances</i> Analyzed by Chromatographic-Mass Spectrometric <i>Analytical Methods</i></u>	<a href="#">TD2022MRPL</a>	1.1	1 January 2022
Detection of Homologous Blood Transfusion (HBT) by Flow Cytometry	<a href="#">TD2026HBT</a>	1.0	1 January 2026

## II. Recently Approved\*\* Versions of Technical Documents:

Title	Document Number	Version Number	Effective Date*
<u>Analytical Testing Procedures</u>	<a href="#">ISL TD2027ATP</a>	1.0	1 January 2027
WADA <u>External Quality Assessment Scheme</u>	<a href="#">ISL TD2027EQAS</a>	1.0	1 January 2027
Laboratory Performance Evaluation	<a href="#">ISL TD2027PERF</a>	1.0	1 January 2027
Minimum Requirements for Validation of <u>Analytical Testing Procedures for Doping Control</u>	<a href="#">ISL TD2027VAL</a>	1.0	1 January 2027
<i>Decision Limits</i> for the Confirmatory Quantification of Exogenous <u>Threshold Substances</u>	<a href="#">ISL TD2027DL</a>	1.0	1 January 2027
Harmonization of Analysis and Reporting of 19-Norsteroids	<a href="#">ISL TD2027NA</a>	1.1	1 January 2027
<u>Minimum Required Performance Levels for Non-Threshold Substances</u> Analyzed by Chromatographic-Mass Spectrometric <u>Analytical Methods</u>	<a href="#">ISL TD2027MRPL</a>	1.1	1 January 2027
<i>Minimum Reporting Levels</i> Applied in <i>Doping Control</i>	<a href="#">ISL TD2027MRL</a>	1.0	1 January 2027
<u>Athlete Passport Management Unit</u> Requirements and Procedures	<a href="#">ISL TD2027APMU</a>	1.0	1 January 2027
Analytical and Reporting Requirements for the Blood <i>Markers</i> of the Steroidal Module of the <i>Athlete Biological Passport</i>	<a href="#">ISL TD2027BSM</a>	1.0	1 January 2027
Analytical and Reporting Requirements for the Blood <i>Markers</i> of the Endocrine Module of the <i>Athlete Biological Passport</i>	<a href="#">ISL TD2027ENDO</a>	1.0	1 January 2027
Analytical and Reporting Requirements for the Urinary <i>Markers</i> of the Steroidal Module of the <i>Athlete Biological Passport</i>	<a href="#">ISL TD2027USM</a>	1.0	1 January 2027

\* Deadline for implementation.

\*\* As per the International Standards for Laboratories, Technical Documents are posted on WADA's website when approved by the WADA Executive Committee.